Xiaoan Wen

Xiaoan Wen

Auto-generated profile, based on publicly available information

Xiaoan Wen

Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjia Xiang, Nanjing 210009, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2021 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
YPYanhong Pan
Yanhong Pan
YYYanping You
Yanping You
LSLi Sun
Li Sun
QSQibang Sui
Qibang Sui
LLLiu Liu
Liu Liu
HSHongbin Sun
Hongbin Sun

10 May 2016 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
CLChao Lin
Chao Lin
XWXiaoan Wen
Xiaoan Wen
HSHongbin Sun
Hongbin Sun
Introduction: Oleanolic acid belongs to the pentacyclic triterpene family. In China, oleanolic acid has been used as an over the counter (OTC) hepatoprotective drug for decades. Oleanolic acid and its derivatives present a wide variety of biological activities, supporting their pharmaceutical uses for multiple diseases. Areas covered: Representative patent publications (1971-2015) covering the preparation, pharmaceutical compositions, and medical uses of oleanolic acid and its derivatives are analyzed, with focus on their anticancer, anti-osteoporosis, anti-obesity, anti-diabetic, lipid-lowering, anti-inflammatory, antioxidant, immune-regulatory, and hepatoprotective effects. A large number of Chinese patents have been given particular attention in this review. Expert opinion: Detailed efficacy studies are highly worth doing to undoubtedly confirm the clinical potential of oleanolic acid and its derivatives. Based on that, it would be critical to identify the key protein targets of the drugs so as to promote drug development and search for new lead compounds. Together, there is a huge potential for drug-repositioning of oleanolic acid, particularly in the areas of metabolic disease and immunological disorders.

1 February 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CCChao Chen
Chao Chen
JSJiemei Song
Jiemei Song
JWJinzheng Wang
Jinzheng Wang
CXChang Xu
Chang Xu
CCCaiping Chen
Caiping Chen
XWXiaoan Wen
Xiaoan Wen

28 April 2017 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
HXHong-Yan Xie
Hong-Yan Xie
LHLi-Shuai Han
Li-Shuai Han
SHShan Huang
Shan Huang
XLXiantao Lei
Xiantao Lei
YCYong Cheng
Yong Cheng
QXQinglong Xu
Qinglong Xu

1 September 2019 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
ELEn-Qin Li
En-Qin Li
WZWei Zhao
Wei Zhao
CZChenxi Zhang
Chenxi Zhang
LQLu-Zhe Qin
Lu-Zhe Qin
SLSheng-Jie Liu
Sheng-Jie Liu
CCCai-Ping Chen
Cai-Ping Chen

1 July 2015 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
CJChunhuan Jiang
Chunhuan Jiang
QXQinglong Xu
Qinglong Xu
XWXiaoan Wen
Xiaoan Wen
HSHongbin Sun
Hongbin Sun
Chronic constipation is a common gastrointestinal disease severely affecting the patient׳s quality of life. The traditional treatment of constipation is the use of laxatives. Recently, several new drugs including lubiprostone, linaclotide and prucalopride have been approved for treatment of chronic constipation. However, a significant unmet medical need still remains, particularly among those patients achieving poor results by current therapies. The 5-HT4 receptor modulators velusetrag and naronapride, the guanylate cyclase C agonist plecanatide and the ileal bile acid transporter inhibitor elobixibat are recognized as the most promising drugs under investigation. Herein, we give a comprehensive review on the pharmacological therapeutics for the treatment of chronic constipation, with the purpose of reflecting the drug development trends in this field.